导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.76% | 1743/4773 |
| 近一周 | -2.28% | 2743/5458 |
| 近一月 | -4.82% | 3101/5421 |
| 近一季 | -5.61% | 2886/5205 |
| 近半年 | -6.41% | 3155/4920 |
| 近一年 | 7.67% | 1430/4361 |
| 近两年 | 71.08% | 963/2954 |
| 近三年 | 37.12% | 810/2253 |
| 成立以来 | -1.64% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.81% 1175/4961 |
18.75% 1349/5312 |
- - |
- - |
| 2025 | 31.15% 1263/4813 |
2.25% 1421/3635 |
1.90% 2032/4076 |
24.49% 1461/4524 |
1.11% 1533/4813 |
| 2024 | 6.73% 1726/3463 |
-2.53% 1372/2808 |
-5.11% 1652/3014 |
15.83% 1615/3129 |
-0.36% 1395/3463 |
| 2023 | -6.05% 806/2656 |
7.50% 566/2280 |
-4.07% 1035/2385 |
-4.60% 1174/2515 |
-4.51% 1066/2655 |
| 2022 | -17.68% 618/2207 |
-13.33% 737/1919 |
3.30% 1175/2016 |
-10.38% 393/2113 |
2.59% 889/2208 |
| 2021 | 16.19% 276/1822 |
-1.54% 511/1255 |
9.30% 567/1330 |
4.59% 333/1466 |
3.23% 458/1822 |
| 2020 | 21.95% 680/1250 |
-4.28% 350/1028 |
16.33% 445/1067 |
6.03% 879/1164 |
3.29% 924/1184 |
| 2019 | 26.13% 583/1092 |
30.24% 256/754 |
-9.45% 655/804 |
0.55% 510/850 |
6.38% 617/918 |
| 2018 | -30.58% 472/834 |
- - |
- - |
- - |
-12.14% 408/691 |
| 2017 | 0.91% 461/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.69% 362/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏中证500ETF联接A VS. 长安沪深300非周期A(740101) |